In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy - PubMed
4 hours ago
- #pyroptosis
- #nanoadjuvant
- #cancer immunotherapy
- A systemic injectable and pyroptosis-enabled nanoadjuvant is developed for personalized cancer immunotherapy.
- The nanoadjuvant induces immunogenic pyroptosis, releasing tumor antigen-rich pyroptosomes, damage-associated molecular patterns, and proinflammatory cytokines.
- A TLR7/8 agonist is photoactivatable released into the pyroptosome, creating an in situ cancer vaccine platform.
- The vaccine activates both innate and adaptive immune responses, eradicating primary tumors and metastatic nodules.
- The approach avoids systemic toxicity and provides long-lasting cancer prevention.
- The study is funded by the National Natural Science Foundation of China and the Beijing Natural Science Foundation.